Company

Eli Lilly

Type: public
Ticker: LLY · NYSE
Market value: $800B

Eli Lilly is public, listed as LLY on NYSE, in Healthcare and pharmaceuticals.

What it sells: Zepbound, Mounjaro, Kisunla (donanemab).

In the language of this map it serves 3 solutions — Weight-loss products and programmes, Chronic-condition pharmaceuticals and Dementia diagnosis and treatment — which between them relieve 5 human frictions.

Its neighbourhood

Everything this entry connects to directly. Click any point to follow it.

Sells

Weight-loss products and programmesMidlife
Chronic-condition pharmaceuticalsMidlife
Dementia diagnosis and treatmentDecline

Human frictions it ultimately relieves

Reached through the solutions above, never directly.

The body starts to fail in ways it did not beforeMidlife
Eating becomes a medical decisionMidlife
Conditions accumulate and specialists multiplyLate career
The body costs more each yearRetirement
The mind fails before the bodyDecline

Trends favouring it

GLP-1 obesity and metabolic drugsCompounding now. Evidence is visible in company results and data.
Longevity biotech and cell/gene therapyReal but not yet at scale. The effects described are expected rather than observed.
Alcohol decline and the sober-curious generationCompounding now. Evidence is visible in company results and data.
Drug shortages, tariffs, and pharma reshoringCompounding now. Evidence is visible in company results and data.